GeneThera, Inc. (GTHR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -8573.00 | -5309.00 | 269.00 | -462.61 Thousand | -97.91 Thousand |
| Net Income | - | -1.01 Million | -774.46 Thousand | -517.65 Thousand | -4.04 Million | -757.72 Thousand |
| Depreciation & Amortization | - | 5280.00 | 5280.00 | 5280.00 | 5280.00 | - |
| Deferred income taxes | - | -509.90 | -14.96 | - | - | - |
| Stock-based compensation | - | 509.9 Thousand | 14.95 Thousand | - | 2.93 Million | 135 Thousand |
| Change in working capital | - | 487.73 Thousand | 748.91 Thousand | 512.64 Thousand | 645.2 Thousand | 519.4 Thousand |
| Other non-cash items | - | 509.9 Thousand | 14.95 Thousand | -502.08 Thousand | -1.00 | 5397.00 |
| Investing Cash Flow | - | - | - | - | - | -26.4 Thousand |
| Investments in PPE | - | - | - | - | - | -26.4 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -26.4 Thousand |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | 26.4 Thousand |
| Financing Cash Flow | - | 8573.00 | - | - | 300 Thousand | 291.96 Thousand |
| Debt repayment | - | -10.82 Thousand | - | - | - | -16.96 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 3400.00 | - | - | 300 Thousand | 275 Thousand |
| Other Financing Activities | - | 16 Thousand | - | - | 300.00 | 16.96 Thousand |
| Accounts receivables | - | - | - | 12 Thousand | - | - |
| Accounts payables | - | 487.73 Thousand | -9982.00 | -28.97 Thousand | 645.2 Thousand | 531.4 Thousand |
| Inventory | - | - | - | -12 Thousand | - | - |
| Other working capital | - | - | 758.89 Thousand | 541.61 Thousand | - | -12 Thousand |
| Cash at beginning of period | - | - | 5309.00 | 5040.00 | 167.65 Thousand | -124.31 Thousand |
| Cash at end of period | - | - | - | 5309.00 | 5040.00 | 167.65 Thousand |
| Capital Expenditure | - | - | - | - | - | -26.4 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | 124.31 Thousand |
| Net cash flow / Change in cash | - | - | -5309.00 | 269.00 | -162.61 Thousand | 291.96 Thousand |
| Free Cash Flow | - | -8573.00 | -5309.00 | 269.00 | -462.61 Thousand | -124.31 Thousand |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | -125.57 Thousand |
| Depreciation & Amortization | - | - | - | - | - | 1320.00 |
| Deferred income taxes | - | - | - | - | - | -13.00 |
| Stock-based compensation | - | - | - | - | - | 13 Thousand |
| Change in working capital | - | - | - | - | - | 117.28 Thousand |
| Other non-cash items | - | - | - | - | - | 13 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | -6034.00 |
| Debt repayment | - | - | - | - | - | -6034.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | -6.03 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | 117.28 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | - | - | - | - |
| Cash at end of period | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | 6034.00 |
FMBRY
ANGO
PCTN
XCHANGING
JCK
OPAL